SYNCHRONY Real-World is a Phase 3 randomized, double-blind, placebo controlled study evaluating the safety and tolerability of EFX in patients with suspected or confirmed clinical diagnosis of ...

I congratulate and thank our team at Morton Plant Hospital for achieving this important milestone in enrolling the first patient in the world’s first confirmatory Phase 3 cardiac cell therapy ...

In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive ...